Skip to main content
Fig. 1 | BMC Ophthalmology

Fig. 1

From: A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study

Fig. 1

Mean change from baseline in BCVA and CRT at Months 3 and 12. *P < 0.0001; **P = 0.0352; ***P < 0.001. P values for BCVA based on a prescpecified exploratory analysis. ∆ represents mean gain in BCVA or mean reduction in CRT. indicates mean number of injections. BCVA: baseline, n = 151; Month 3, n = 135; Month 12, n = 93. CRT: Baseline, n = 151; Month 3, n = 130; Month 12, n = 85. BCVA, best-corrected visual acuity; CRT, central retinal thickness; ITT, intent-to-treat; n, number of patients

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us